New Delhi, India -- (SBWire) -- 03/08/2018 --Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).

According to the latest report of DelveInsight, "Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market", the number of Diagnosed Prevalent Population of Transthyretin Amyloidosis were estimated to be around 19,160 cases in 2016. Out of all the diagnosed cases the number of treatable cases of Transthyretin Amyloidosis were around 9,545 cases in 2016. Among sub-type specific cases FAC accounted for a higher number of amyloidosis cases as compared to FAP. United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.

Region-wise market size analysis of the indication has shown that among 7MM US accounts for the highest market size, followed by EU5 and Japan. The therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016. Among EU5 countries, Germany has the highest market size while Spain has the lowest market size. Vyndaqel (tafamidis meglumine) by Pfizer is the only approved therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic Polyneuropathy in Europe and for all stages in Japan. Vyndaqel is expected to enter the 7MM by mid of 2023 for TTR-CM, creating chances for a huge increment on the market value of the respective drug.

Currently, the treatment regimens are dominated by symptomatic therapies, where Liver Transplantation and Carpal Tunnel surgery is recommended, based on the symptoms of patients. The market is expected to grow significantly with the launch of upcoming drugs: Patisiran (Alnylam Pharmaceuticals) and Inotersen (Ionis Pharmaceuticals Inc.) in 2018 and CRX-1008 (Corino Therapeutics Inc) in 2023. The report has covered approximately15 pipeline products out of which around 8 are in the clinical development phase. Detailed historical and forecasted market analysis covering 7MM from 2015-2027 has been provided. Market size by therapy covering 7MM is provided to better understand the market distribution and major players. Historical, as well as the forecasted epidemiology of the disease in the 7MM covering all the major details of the indication, is provided.

Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the Transthyretin Amyloidosis market.
- To understand the future market competition in the Transthyretin Amyloidosis market and Insight reviews of the key market drivers and barriers.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

- Pfizer
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals Inc.
- Corino Therapeutics Inc.
- Proclara Bioscience
- Arcturus Therapeutics

Table of Contents:
1. Report Introduction
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2027
3. Disease Background and Overview: Transthyretin-related amyloidosis
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis
3.4. Causes
3.5. Symptoms
3.6. Pathogenesis
3.7. Diagnosis
3.7.1. Tools for evaluating TTR-FAP progression
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of ATTR
4.4. Type-specific Diagnosed Prevalent Population of ATTR in 7MM
5. Epidemiology by Country
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. European Union Five
5.2.1. United Kingdom
5.2.1.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.2.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.2.1.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.2.2. Germany
5.2.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.2.3. Italy
5.2.3.1. Diagnosed Prevalent Population of ATTR in Italy
5.2.3.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.2.3.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.2.4. Spain
5.2.4.1. Diagnosed Prevalent Population of ATTR in Spain
5.2.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.2.4.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.2.5. France
5.2.5.1. Diagnosed Prevalent Population of ATTR in France
5.2.5.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.2.5.3. Treatable cases of Transthyretin Amyloidosis in France
5.3. Japan
5.3.1. Diagnosed Prevalent Population of ATTR in Japan
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.3.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. 7MM Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United States
6.2. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United Kingdom
6.3. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany
6.4. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy
6.5. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France
6.6. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan
7. Current Treatment and Medical Practices
7.1. Treatment Guidelines
7.1.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Therapeutics under Development by Companies
10.1. Key Cross Competition
10.2. Clinical Products (Phase III to Phase I]
10.2.1. Patisiran: Alnylam Pharmaceuticals
10.2.1.1. Regulatory Milestones
10.2.1.2. Other development activities
10.2.1.3. Clinical Development
10.2.1.4. Clinical Trials Information
10.2.1.5. Safety and Efficacy
10.2.1.6. Product Profile
10.2.2. Inotersen: Ionis Pharmaceuticals Inc.
10.2.2.1. Regulatory Milestones
10.2.2.2. Other development activities
10.2.2.3. Clinical Development
10.2.2.4. Clinical Trials Information
10.2.2.5. Safety and Efficacy
10.2.2.6. Product Profile
10.2.3. CRX-1008: Corino Therapeutics Inc.
10.2.3.1. Regulatory Milestones
10.2.3.2. Other development activities
10.2.3.3. Clinical Development
10.2.3.4. Clinical Trials Information
10.2.3.5. Safety and Efficacy
10.2.3.6. Product Profile
To be continued in the report...
10.3. Non-Clinical Products
10.3.1. NPT189: Proclara Bioscience
10.3.1.1. Drug Description
10.3.1.2. Pre-Clinical results
10.3.1.3. Other development activities
10.3.1.4. Product Profile
10.3.2. LUNAR-101: Arcturus Therapeutics
10.3.2.1. Drug Description
10.3.2.2. Pre-Clinical results
10.3.2.3. Other development activities
10.3.2.4. Product Profile
To be continued in the report…
11. Therapeutic Assessment
11.1. Assessment by Monotherapy Products
11.2. Assessment by Combination Products
11.3. Assessment by Route of Administration
11.4. Assessment by Stage and Route
11.5. Assessment by Molecule Type
11.6. Assessment by Stage and Molecule Type
11.7. Assessment by Domain
11.8. Assessment by Stage and Domain
12. Transthyretin Amyloidosis: Market Analysis
12.1. Transthyretin Amyloidosis: 7 Major Market Outlook
12.1.1. Market size of Transthyretin Amyloidosis in 7MM
12.1.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
13. Market Outlook by Country
13.1. Transthyretin Amyloidosis: United States Market Analysis
13.1.1. United States Market size
13.1.2. Therapy-Based Market Size of Transthyretin Amyloidosis
13.2. Transthyretin Amyloidosis: EU5 Market Analysis
13.2.1. Germany
13.2.1.1. Germany Market size
13.2.1.2. Therapy Based Market Size of Transthyretin Amyloidosis
13.2.2. France
13.2.2.1. France Market size
13.2.2.2. Therapy Based Market Size of Transthyretin Amyloidosis
13.2.3. United Kingdom
13.2.3.1. United Kingdom Market size
13.2.3.2. Therapy Based Market Size of Transthyretin Amyloidosis
13.2.4. Spain
13.2.4.1. Spain Market size
13.2.4.2. Therapy Based Market Size of Transthyretin Amyloidosis
13.2.5. Italy
13.2.5.1. Italy Market size
13.2.5.2. Therapy Based Market Size of Transthyretin Amyloidosis
13.3. Transthyretin Amyloidosis: Japan Market Analysis
13.3.1. Japan Market size
13.3.2. Therapy Based Market Size of Transthyretin Amyloidosis
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources Used
18. DelveInsight Capabilities
19. Disclaimer

For sample pages:
Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market 2027 : https://www.delveinsight.com/report-store/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-and-market

Other Related Reports:
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Insight, 2017 : https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrade-s-disease-pipeline-insight

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Market Insight, Epidemiology and Market Forecast - 2027 : https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrade-s-disease-market-insight-epidemiology-and-market-forecast

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Epidemiology Forecast to 2025 : https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrade-s-disease-epidemiology-forecast

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.